+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Veterinary Diagnostic Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 194 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5613052
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The veterinary diagnostic market is rapidly evolving as innovation and digital transformation reshape clinical capabilities, supply chain strategies, and operational models. Industry leaders and investors now face a landscape defined by predictive analytics, integrated platforms, and a growing complexity in animal health management.

Veterinary Diagnostic Market Snapshot

The global veterinary diagnostic market grew from USD 3.63 billion in 2024 to USD 3.89 billion in 2025. It is projected to expand at a CAGR of 7.72%, reaching USD 6.59 billion by 2032. Market growth is driven by steady advancements in diagnostic technologies, increasing demand for faster and more accurate disease detection, and growing animal health awareness across companion, livestock, poultry, and aquaculture segments. Technology adoption and regional diversity present both opportunities and challenges for businesses seeking to achieve operational excellence.

Scope & Segmentation of the Veterinary Diagnostic Market

This report delivers a comprehensive outlook on the veterinary diagnostic landscape, segmenting by products, animal categories, test modalities, technologies, diseases, end users, and global regions. Key segmentation highlights include:

  • Product Type: Instruments, reagents, software and services including consulting, data management, and training.
  • Animal Type: Aquaculture, companion animals, equine, livestock, and poultry.
  • Test Type: Clinical biochemistry, hematology, imaging, immunodiagnostics, microbiology, and molecular diagnostics.
  • Sample Type: Serum and plasma, tissue, urine, and whole blood.
  • Technology: Flow cytometry, immunoassays, next-generation sequencing, and polymerase chain reaction (PCR).
  • Disease Type: Genetic disorders, infectious diseases (bacterial, fungal, parasitic, viral), metabolic, and neoplastic disorders.
  • End User: Academic and research institutes, diagnostic laboratories, point of care testing sites, and veterinary hospitals.
  • Region: Americas (North America, Latin America), Europe, Middle East, Africa, Asia-Pacific. Major country markets include the United States, Canada, Brazil, United Kingdom, Germany, China, India, and others.
  • Key Companies: Zoetis Inc., Virbac S.A., IDEXX Laboratories, Inc., Neogen Corporation, Thermo Fisher Scientific Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., and others.

Key Takeaways for Senior Decision-Makers

  • The ongoing digital transformation is changing how laboratory and veterinary professionals manage samples, analyze results, and integrate diagnostics into patient care, supporting faster decision-making and improved outcomes.
  • Growing regulatory demands and tighter accreditation standards are driving investments in more advanced molecular assays, digital platforms, and automated workflows, highlighting the need for continuous R&D and quality upgrades.
  • End-user needs vary widely: laboratories and hospitals are adopting high-throughput analyzers, while point-of-care settings and emerging geographies often prioritize portable and affordable solutions.
  • Companies are increasingly shifting toward recurring revenue service models, such as software subscriptions and bundled consulting, to enhance customer retention and adapt to evolving procurement practices.
  • Collaboration between technology developers, veterinarians, and research institutions is accelerating the pace of innovation, ensuring that diagnostic products address both routine health needs and emerging disease threats.
  • Regional differences shape demand, with North America focusing on integration and reimbursement, Latin America on cost-efficient solutions, Europe on automation, Asia-Pacific on scalability, and Africa and the Middle East on mobility and supply chain resilience.

Tariff Impact on Supply Chain and Cost Structures

Recent United States tariffs have imposed cost pressures throughout the veterinary diagnostic supply chain, especially for specialized reagents and instruments. Industry response includes renegotiating supplier contracts, expanding local sourcing, and optimizing logistics. These adaptive strategies enhance supply chain robustness and support market competitiveness despite regulatory and cost volatility.

Methodology & Data Sources

This report combines extensive secondary research with targeted primary interviews involving veterinary practitioners, laboratory leaders, technology providers, and regulatory professionals. Data triangulation and in-depth analysis ensure reliable, actionable insights aligned with the real-world perspectives and challenges of market stakeholders.

Why This Report Matters to B2B Decision-Makers

  • Supports evidence-based strategy development with detailed, segment-level insights and a granular view of growth drivers, challenges, and opportunities in the veterinary diagnostics market.
  • Enables more agile procurement and operational decisions by analyzing supply chain trends, technology adoption patterns, and regional market shifts.
  • Delivers a roadmap for leveraging innovation, digital tools, and partnerships to strengthen competitive positioning and future-proof business models in animal health diagnostics.

Conclusion

The veterinary diagnostic market is defined by technological advancements, regional dynamics, and evolving value chains. Senior decision-makers using this analysis can anticipate shifts, prioritize investment, and achieve stronger outcomes in a dynamic, competitive environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Rising investment in novel nanoparticle-based fenbendazole delivery for improved bioavailability
5.2. Expansion of fenbendazole combined therapy clinical trials targeting human oncology applications
5.3. Growing number of generic fenbendazole suppliers intensifying price competition in veterinary markets
5.4. Regulatory approvals for extended-release fenbendazole formulations shaping livestock parasite control
5.5. Surge in online direct-to-consumer sales channels accelerating non-prescription fenbendazole distribution
5.6. Research into fenbendazole resistance patterns prompting development of combination anthelmintic protocols
5.7. Strategic partnerships between biotech firms and animal health companies to develop fenbendazole derivatives
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Fenbendazole Market, by Animal Type
8.1. Aquaculture
8.1.1. Fish
8.1.2. Shrimp
8.2. Companion Animal
8.2.1. Cat
8.2.2. Dog
8.3. Livestock
8.3.1. Cattle
8.3.2. Sheep & Goat
8.3.3. Swine
9. Fenbendazole Market, by Form
9.1. Granules
9.2. Oral Suspension
9.3. Powder
9.4. Tablet
10. Fenbendazole Market, by Distribution Channel
10.1. Online Pharmacies
10.2. Retail Pharmacies
10.3. Veterinary Hospitals & Clinics
11. Fenbendazole Market, by Application
11.1. Hookworm Treatment
11.2. Lungworm Treatment
11.3. Roundworm Treatment
11.4. Whipworm Treatment
12. Fenbendazole Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Fenbendazole Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Fenbendazole Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Zoetis LLC
15.3.2. Elanco Animal Health Incorporated
15.3.3. Boehringer Ingelheim International GmbH
15.3.4. Merck & Co., Inc.
15.3.5. Ceva Santé Animale S.A.
15.3.6. Vetoquinol S.A.
15.3.7. Virbac S.A.
15.3.8. Dechra Pharmaceuticals PLC
15.3.9. Norbrook Laboratories Limited
15.3.10. Zhejiang NHU Co., Ltd.

Companies Mentioned

The companies profiled in this Veterinary Diagnostic market report include:
  • Zoetis Inc.
  • Virbac S.A.
  • IDEXX Laboratories, Inc.
  • Neogen Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Agrolabo S.p.A.
  • Biogal Galed Labs
  • BioMérieux S.A.
  • BioNote USA, Inc.
  • Demeditec Diagnostics GmbH
  • Eurofins Scientific SE
  • Fassisi GmbH
  • FUJIFILM Holdings Corporation
  • Mars, Incorporated
  • Promega Corporation
  • Randox Laboratories, Ltd.
  • Shenzhen Mindray Animal Medical Technology Co., Ltd.
  • Vimian Group AB
  • SAN Group Biotech Germany GmbH
  • Meridian Bioscience, Inc.

Table Information